EP0397821A4 - A novel family of high affinity, modified antibodies for cancer treatment - Google Patents

A novel family of high affinity, modified antibodies for cancer treatment

Info

Publication number
EP0397821A4
EP0397821A4 EP19890911974 EP89911974A EP0397821A4 EP 0397821 A4 EP0397821 A4 EP 0397821A4 EP 19890911974 EP19890911974 EP 19890911974 EP 89911974 A EP89911974 A EP 89911974A EP 0397821 A4 EP0397821 A4 EP 0397821A4
Authority
EP
European Patent Office
Prior art keywords
high affinity
cancer treatment
modified antibodies
novel family
family
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19890911974
Other languages
English (en)
Other versions
EP0397821A1 (en
Inventor
Peter Mezes
Brian Gourlie
Mark Rixon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dow Chemical Co
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Publication of EP0397821A1 publication Critical patent/EP0397821A1/en
Publication of EP0397821A4 publication Critical patent/EP0397821A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP19890911974 1988-10-19 1989-10-04 A novel family of high affinity, modified antibodies for cancer treatment Withdrawn EP0397821A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25994388A 1988-10-19 1988-10-19
US259943 1988-10-19

Publications (2)

Publication Number Publication Date
EP0397821A1 EP0397821A1 (en) 1990-11-22
EP0397821A4 true EP0397821A4 (en) 1992-03-18

Family

ID=22987104

Family Applications (2)

Application Number Title Priority Date Filing Date
EP19890911974 Withdrawn EP0397821A4 (en) 1988-10-19 1989-10-04 A novel family of high affinity, modified antibodies for cancer treatment
EP89119361A Expired - Lifetime EP0365997B1 (en) 1988-10-19 1989-10-18 A novel family of high affinity, modified antibodies for cancer treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP89119361A Expired - Lifetime EP0365997B1 (en) 1988-10-19 1989-10-18 A novel family of high affinity, modified antibodies for cancer treatment

Country Status (21)

Country Link
EP (2) EP0397821A4 (fi)
JP (1) JP2935520B2 (fi)
KR (1) KR0161525B1 (fi)
AR (1) AR242434A1 (fi)
AT (1) ATE111519T1 (fi)
AU (2) AU4429989A (fi)
BR (1) BR8907126A (fi)
CA (1) CA2000913C (fi)
DE (1) DE68918217T2 (fi)
DK (1) DK173089B1 (fi)
ES (1) ES2059670T3 (fi)
FI (1) FI103181B1 (fi)
HK (1) HK162795A (fi)
HU (1) HU218093B (fi)
IE (1) IE64966B1 (fi)
IL (1) IL92037A (fi)
NO (1) NO301075B1 (fi)
NZ (1) NZ231012A (fi)
PT (1) PT92013B (fi)
WO (1) WO1990004410A1 (fi)
ZA (1) ZA897858B (fi)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5976531A (en) * 1990-04-19 1999-11-02 The Dow Chemical Company Composite antibodies of human subgroup IV light chain capable of binding to tag-72
US6495137B1 (en) * 1990-04-19 2002-12-17 The Dow Chemical Company Humanized anti-tag-72 monoclonal antibodies using human subgroup 4 kappa light chains
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
IE922287A1 (en) * 1991-07-15 1993-01-27 Wellcome Found Production of antibodies
US6025165A (en) * 1991-11-25 2000-02-15 Enzon, Inc. Methods for producing multivalent antigen-binding proteins
EP0618969B1 (en) * 1991-12-13 2003-06-25 The Dow Chemical Company Composite antibodies of human subgroup iv light chain capable of binding to tag-72
AU696627B2 (en) * 1991-12-13 1998-09-17 Dow Chemical Company, The Composite antibodies of human subgroup IV light chain capable of binding to TAG-72
WO1994012520A1 (en) * 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
JP3312357B2 (ja) 1992-12-11 2002-08-05 ザ ダウ ケミカル カンパニー 多価の一本鎖抗体
US6348581B1 (en) 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
CA2321932A1 (en) * 1998-02-25 1999-09-02 The Dow Chemical Company High affinity humanized anti-tag-72 monoclonal antibodies
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
US7319139B2 (en) 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
WO2004003155A2 (en) 2002-06-28 2004-01-08 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
DE10311248A1 (de) * 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
WO2005021594A2 (en) 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US73685A (en) * 1868-01-21 Improvement in ploughs
WO1989001783A2 (en) * 1987-09-04 1989-03-09 Celltech Limited Recombinant antibody and method

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2788040B1 (fr) * 1998-12-31 2001-03-23 Airsec Sa Distributeur d'objets

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US73685A (en) * 1868-01-21 Improvement in ploughs
WO1989001783A2 (en) * 1987-09-04 1989-03-09 Celltech Limited Recombinant antibody and method

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 110, no. 13, 27th March 1989, page 546, abstract no. 113055e, Columbus, Ohio, US; & US-A-73 685 (UNITED STATES DEPT. OF HEALTH AND HUMAN SERVICES) 01-03-1988 *
See also references of WO9004410A1 *

Also Published As

Publication number Publication date
AR242434A1 (es) 1993-03-31
CA2000913A1 (en) 1990-04-19
ATE111519T1 (de) 1994-09-15
PT92013B (pt) 1995-07-06
ES2059670T3 (es) 1994-11-16
HU896255D0 (en) 1991-09-30
HK162795A (en) 1995-10-27
NO902696D0 (no) 1990-06-18
NO902696L (no) 1990-08-16
HUT56878A (en) 1991-10-28
PT92013A (pt) 1990-04-30
IL92037A (en) 1998-03-10
FI903056A0 (fi) 1990-06-18
KR900701302A (ko) 1990-12-01
EP0365997A3 (en) 1992-03-04
DE68918217T2 (de) 1995-02-09
JPH03502889A (ja) 1991-07-04
DK173089B1 (da) 2000-01-10
IE64966B1 (en) 1995-09-20
EP0365997B1 (en) 1994-09-14
NZ231012A (en) 1993-02-25
IE893347L (en) 1990-04-19
EP0365997A2 (en) 1990-05-02
AU633026B2 (en) 1993-01-21
AU4429989A (en) 1990-05-14
AU4354089A (en) 1990-04-26
DE68918217D1 (de) 1994-10-20
EP0397821A1 (en) 1990-11-22
ZA897858B (en) 1991-06-26
CA2000913C (en) 1999-02-16
HU218093B (hu) 2000-05-28
FI103181B (fi) 1999-05-14
BR8907126A (pt) 1991-02-13
FI103181B1 (fi) 1999-05-14
KR0161525B1 (ko) 1998-12-01
WO1990004410A1 (en) 1990-05-03
DK149990D0 (da) 1990-06-19
IL92037A0 (en) 1990-07-12
DK149990A (da) 1990-08-17
JP2935520B2 (ja) 1999-08-16
NO301075B1 (no) 1997-09-08

Similar Documents

Publication Publication Date Title
AR242434A1 (es) Un proceso para preparar un anticuerpo o fragmento de anticuerpo.
GB8905669D0 (en) Modified antibodies
HU906891D0 (en) New antibodies reactive by human carcinoma
RO105652B1 (ro) Procedeu de reducere a heterogenitatii anticorpilor monoclonali
IL90017A0 (en) Monoclonal antibodies
ZA898777B (en) Monoclonal antibodies
HUT48909A (en) Process for production of conjugates of anti-bodies
ZA89258B (en) Monoclonal antibodies
AU618720B2 (en) Monoclonal antibodies
GB8820036D0 (en) Monoclonal antibodies
GB8927389D0 (en) Monoclonal antibodies
AU4668889A (en) Monoclonal antibodies specific for tumor antigens
EP0344112A3 (en) Substituted bisacyloxynaphthacenes, and process for the preparation of tetrathiotetracenes
EP0252768A3 (en) Anti-lafora body monoclonal antibody
YU63490A (en) Process for synthesis of n-methyl-3,4-dimetoxyphenylethylamine
AU6482190A (en) Process for the preparation of heme/hemin
EP0353295A4 (en) NOVEL IMPROVED ANTIBODIES FOR SITE SPECIFIC FIXING OF COMPOUNDS.
GB9318912D0 (en) Humanised antibodies
AU612766C (en) Monoclonal antibodies
AU612122C (en) Monoclonal antibodies
GB8820035D0 (en) Monoclonal antibodies
GB8812962D0 (en) Monoclonal antibodies
GB8812963D0 (en) Monoclonal antibodies
ZA892882B (en) Monoclonal antibodies
GB8812353D0 (en) Antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19900618

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19920130

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19920425